Pitfalls And Hopes in Down Syndrome Therapeutic Approaches: In the Search for Evidence-Based Treatments
- 7 March 2006
- journal article
- review article
- Published by Springer Nature in Behavior Genetics
- Vol. 36 (3) , 454-468
- https://doi.org/10.1007/s10519-006-9050-2
Abstract
Trisomy 21 or Down syndrome (DS) is a complex syndrome, of genetic origin with multiple and variable neurobiological and neuropsychological manifestations. DS patients have consistent signs of brain damage along their lives, but understanding the biology of DS is complicated due to the extraordinary heterogeneity of the phenotypic signs. Thus, treatment of DS mental retardation poses significant challenges for clinicians and scientists. The review addresses the classical pharmacological and environmental treatments and also critically reviews the new possibilities that are emerging from the exciting advances in gene or cell therapy. We describe some of the most recent developments in the field and give a sense of the prospects for future prevention and therapy.Keywords
This publication has 85 references indexed in Scilit:
- Can cognitive deterioration associated with Down syndrome be reduced?Medical Hypotheses, 2005
- Attenuation of α2A-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthoodNeuroscience, 2004
- Down's syndrome astrocytes have greater antioxidant capacity than euploid astrocytesEuropean Journal of Neuroscience, 2004
- RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxiaNature Medicine, 2004
- In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult ratsThe Journal of Gene Medicine, 2003
- Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced areaGene Therapy, 2003
- Increased superoxide dismutase and Down’s syndromeMedical Hypotheses, 2001
- Oestrogen and nerve growth factor – neuroprotection and repair in Alzheimer’s diseaseExpert Opinion on Investigational Drugs, 2000
- Effectiveness of Early Intervention for Vulnerable Children: A Developmental PerspectiveAmerican Journal on Mental Retardation, 1997
- PiracetamDrugs & Aging, 1991